Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Parp'
Parp published presentations and documents on DocSlides.
PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update
by ellena-manuel
Program Overview . Discussion Outline. DNA Repair...
PARP Inhibitors This program will include a discussion of off-label treatment and investigational a
by conchita-marotz
PARP Inhibitors: What Do We know?. PARP Inhibitor...
PARP Inhibitors and Cancer: What Do You Need to Know?
by pasty-toler
This program will include a discussion of off-lab...
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor,
by marina-yarberry
Niraparib. and . Temozolomide. in Patients with...
The Use of PARP Inhibitors in Breast Cancer: Challenges
by calandra-battersby
and Opportunities. This program will include a di...
by medshair
Five-year . survival. 15%. 30%. 40%. ?50%?. First ...
by littleccas
actual. . video-recorded proceedings from the . l...
Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i
by zen
knowledge. ). Incorporate evidence-based research ...
1 Svetlana Jeremić 1 , Ana Kesić
by esther
2. , Jelena Đorović Jovanović. 2. , Biljana Pet...
GU CONNECT PARP inhibitors in Prostate Cancer
by jocelyn
Latest developments. . Prof.. . Neeraj Agarwal, ...
Arsenic-Induces Dysfunction in Poly(ADP-Ribose) Polymerase-1:
by holly
Arsenic Contamination in Potable Water and an Asse...
Policies Procedures and Documents
by naomi
Course Loads Full-Time and Half-Time DesignationPa...
A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy
by bikersjoker
patients with . advanced breast . cancer and a ger...
Please note, these are the actual video-recorded
by blindnessinfluenced
proceedings from the live CME event and may includ...
Updates in Ovarian Cancer Care
by ellena-manuel
Lisa McCluskey, MD. Gynecologic Oncologist. June ...
Patient Selection for PARP
by sherrill-nordquist
Inhibitors:. Purpose and Practicalities . Present...
ASCO 2019 NSCLC - PARP & Chemotherapy
by mitsue-stanley
ASCO 2019 NSCLC - PARP & Chemotherapy REF Stu...
The Nurse View: Clinical Considerations in the Management of
by natalia-silvester
BRCA. -Mutated Advanced Ovarian Cancer. Moderator...
Cancer Chemotherapy Part I: General Cancer Chemotherapy
by ellena-manuel
Chapter 16; Pages 797 to 815A. also Section 16.11...
Precision Medicine in the management of gynecologic cancers
by stefany-barnette
Randal West, MD. Ovarian cancer standard of care....
Updates in Ovarian Cancer Care
by tatiana-dople
Lisa McCluskey, MD. Gynecologic Oncologist. June ...
Case Discussion: Second
by celsa-spraggs
Opinion. 55 year-old woman with . recurrent . ova...
State of the Art in BRCA
by ellena-manuel
-Mutated Ovarian Cancer. This program will includ...
Growth Patterns and Pathobiology of Experimental and
by pamella-moone
Clinical Malignancies. In Vivo. Updated: March . ...
Service Provider Application
by sherrill-nordquist
NYC Recovers Fiscal Year 201 6 I. OVERVIEW ParP of...
A Cancer
by stefany-barnette
Knowledge Network. Accelerate . cancer R&D. B...
PCR Application:
by alexa-scheidler
Can Breast Cancer be Cured?. Normal, Healthy Cell...
Store at C Cleaved PARP Asp Antibody Human Specic rev
by natalia-silvester
022213 Small 100 57525l 10 western blots Large 30...
ParP of SP VincenP’s HospiPal and a CollaNoraPive CenPre of The
by min-jolicoeur
Sedation in Palliative Care Presented by: Jennifer...
Load More...
